What is the most effective tool for detecting prostate cancer using a standard MR scanner?

Magnetic Resonance in Medical Sciences

Volumn 12, Issue 4, 2013, Pages 271-280

  Osugi, Kei ^a   Tanimoto, Akihiro ^a   Nakashima, Jun ^b   Shinoda, Kazunobu ^a   Hashiguchi, Akinori ^a   Oya, Mototsugu ^a   Jinzaki, Masahiro ^a   Kuribayashi, Sachio ^a  

^a KEIO UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Apparent diffusion coefficient; Diffusion weighted imaging; Prostate cancer

Indexed keywords

AGED; ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; HUMAN; IMAGE ENHANCEMENT; MALE; METHODOLOGY; MIDDLE AGED; OBSERVER VARIATION; PATHOLOGY; PROSTATE TUMOR; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

AGED; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; OBSERVER VARIATION; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84891513323     PISSN: 13473182     EISSN: 18802206     Source Type: Journal    
DOI: 10.2463/mrms.2012-0054     Document Type: Article

References (29)

1. Carroll PR, Presti JC Jr, Small E, Roach M 3rd. Focal therapy for prostate cancer 1996: maximizing outcome. Urology 1997; 49 (3A Suppl): 84-94.
2. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: Individual countries. BJU Int 2002; 90: 174-184.
3. Padhani AR, Liu G, Koh DM, et al. Diffusionweighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-125.
4. Turkbey B, Shah VP, Pang Y, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 2011; 258: 488-495.
5. Kajihara H, Hayashida Y, Murakami R, et al. Usefulness of diffusion-weighted imaging in the localization of prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74: 399-403.
6. Shimizu T, Nishie A, Ro T, et al. Prostate cancer detection: the value of performing an MRI before a biopsy. Acta Radiol 2009; 50: 1080-1088.
7. Rosenkrantz AB, Mannelli L, Kong X, et al. Prostate cancer: utility of fusion of T2-weighted and high b-value diffusion-weighted images for peripheral zone tumor detection and localization. J Magn Reson Imaging 2011; 34: 95-100.
8. Wang R, Chen JJ, Zhou YC, Huang MM, Zhang XR, Miao HD. Evaluation of diffusion-weighted magnetic resonance imaging and contrast-enhanced harmonic ultrasonography in detection and location of prostate transition-zone cancer. J Int Med Res 2011; 39: 256-266.
9. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuibayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007; 25: 146-152.
10. Yoshimitsu K, Kiyoshima K, Irie H, et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging 2008; 27: 132-139.
11. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusionweighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology. J Magn Reson Imaging 2006; 24: 108-113.
12. Yoshizako T, Wada A, Hayashi T, et al. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol 2008; 49: 1207-1213.
13. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K. Prostate cancer detection with 3T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging 2010; 31: 625-631.
14. Sobin LH, Gospadarowicz MK, Wittekind C, eds. TNM classiffiation of malignant tumors, seventh edition. Oxford: Wiley-Blackwell, 2009.
15. Qayyum A, Coakley FV, Lu Y, et al. Organ conned prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2004; 183: 1079-1083.
16. Shimofusa R, Fujimoto H, Akamata H, et al. Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr 2005; 29: 149-153.
17. Rouvière O, Raudrant A, Ecochard R, et al. Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol 2003; 13: 931-942.
18. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004; 22: 275-282.
19. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion weighted imaging of normal and malignant prostate tissue at 3. 0T. J Magn Reson Imaging 2006; 23: 130-134.
20. Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3. 0 tesla. Invest Radiol 2006; 41: 185-188.
21. Kumar V, Jagannathan NR, Kumar R, et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn Reson Imaging 2006; 24: 541-548.
22. Reinsberg SA, Payne GS, Riches SF, et al. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR Am J Roentgenol 2007; 188: 91-98.
23. Tamada T, Sone T, Jo Y, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008; 28: 720-726.
24. Kitajima K, Takahashi S, Ueno Y, et al. Clinical utility of apparent diffusion coefficient values obtained using high b-value when diagnosing prostate cancer using 3 tesla MRI: comparison between ultra-high b-value (2000 s/mm2) and standard high b-value (1000 s/mm2). J Magn Reson Imaging 2012; 36: 198-205.
25. Li H, Sugimura K, Kaji Y, et al. Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. AJR Am J Roentgenol 2006; 186: 729-742.
26. Ishida J, Sugimura K, Okizuka H, et al. Benign prostatic hyperplasia: value of MR imaging for determining histologic type. Radiology 1994; 190: 329-331.
27. Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010; 257: 715-723.
28. Tamada T, Sone T, Higashi H, et al. Prostate cancer detection in patients with total serum prostatespeci ffi antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR Am J Roentgenol 2011; 197: 664-670.
29. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical signiffiance for treatment of prostate cancer. Cancer 1993; 71(3 Suppl): 933-938.